A Multi-Provincial Clinical Evaluation of the PANBIO™ COVID-19 Antigen Rapid Test Device in South Africa
Diagnostics · 20.07.2026 · 16 (14) · 2263
DOI: 10.3390/diagnostics16142263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 20.07.2026. Verfasst von Vidya Keshav und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wits Diagnostic Innovation Hub, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Fund, Abbott Rapid Diagnostics.
Abstract (Originalsprache)
Background
Rapid antigen tests were widely utilised during the COVID-19 pandemic to expand diagnostic access in resource-limited settings. However, prospective evaluations under intended-use conditions remained essential to define their role in decentralised testing strategies.
Methods
We conducted a prospective multi-provincial clinical evaluation of the Panbio™ COVID-19 Antigen Rapid Test Device in South Africa between July 2021 and January 2022. Paired nasal and nasopharyngeal swabs were collected from 609 participants across three geographically diverse South African provinces. Antigen test results were compared with standard-of-care TaqPath RT-PCR, with BD MAX™ RT-PCR included as a secondary molecular comparator. Performance was assessed by viral load, symptom status, and variant predominance periods.
Results
Standard-of-care RT-PCR identified 136 positive cases (22.3% prevalence). The Panbio™ test demonstrated overall sensitivity of 80.1% (95% CI: 72–87) and specificity of 98.5% (95% CI: 97–99). Sensitivity reached 90.1% in specimens with Ct values ≤25 and 85.2% among symptomatic participants tested within seven days of onset but declined at Ct values ≥30 and in asymptomatic individuals. Performance remained consistent during Delta- and Omicron-predominant periods.
Discussion
The Panbio™ RDT demonstrates high diagnostic accuracy for detecting SARS-CoV-2 in individuals with high viral load, supporting its use for rapid identification of infectious cases during transmission surges. Molecular testing remains necessary for low viral load infections and asymptomatic screening.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wits Diagnostic Innovation Hub, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2050, South Africa.
- Desmond Tutu HIV Centre, University of Cape Town, Cape Town 7925, South Africa.
- National Priority Program, National Health Laboratory Service, Johannesburg 2131, South Africa.
ORCID-Profile: Vidya Keshav, Lesley Scott, Anura David
Förderung
- Abbott Fund
- Abbott Rapid Diagnostics
Zitieren
APA
Keshav, V., Scott, L., David, A., Pike, C., Bekker, L. G., & Stevens, W. (2026). A Multi-Provincial Clinical Evaluation of the PANBIO™ COVID-19 Antigen Rapid Test Device in South Africa. Diagnostics, 16(14), 2263. https://doi.org/10.3390/diagnostics16142263
Vancouver
Keshav V, Scott L, David A, Pike C, Bekker LG, Stevens W. A Multi-Provincial Clinical Evaluation of the PANBIO™ COVID-19 Antigen Rapid Test Device in South Africa. Diagnostics. 2026;16(14):2263. doi:10.3390/diagnostics16142263
BibTeX
@article{Keshav2026,
author = {Keshav, Vidya and Scott, Lesley and David, Anura and Pike, Carey and Bekker, Linda-Gail and Stevens, Wendy},
title = {A Multi-Provincial Clinical Evaluation of the PANBIO™ COVID-19 Antigen Rapid Test Device in South Africa},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {14},
pages = {2263},
doi = {10.3390/diagnostics16142263}
}
EUVIMED